OMTO, Volume *22*

Supplemental information

TBC1D3 family is a prognostic biomarker and correlates with immune infiltration in kidney renal clear cell carcinoma

Bei Wang, Dandan Chen, and Haiying Hua

Supplementary table 1. TBC1D3 family expression based on Race, Gender, Age, Tumor grade, ccRCC subtypes and Nodal metastasis status

	TBC1D3	TBC1D3B	Sig TBC1D3C	TBC1D3G	TBC1D3H
Race					
Normal vs Caucasian	**1.00E-12**	**1.62E-12**	**1.62E-12**	**1.62E-12**	**1.62E-12**
Normal vs AfricanAmerican	**8.48E-08**	**5.49E-10**	**2.13E-05**	**1.38E-04**	**1.38E-04**
Normal vs Asain	**1.28E-02**	1.03E-01	5.08E-02	2.57E-01	2.57E-01
Caucasian vs AfricanAmerican	8.31E-01	**3.02E-02**	**4.79E-02**	**1.89E-02**	**1.89E-02**
Caucasian vs Asian	**1.03E-02**	2.57E-01	4.38E-01	3.85E-01	3.84E-01
AfricanAmerican vs Asian	**3.81E-02**	3.80E-01	7.40E-01	6.53E-01	6.53E-01
Gender					
Normal vs Male	**1.62E-12**	**1.00E-12**	**1.00E-12**	**3.09E-12**	**3.09E-12**
Normal vs Female	**1.62E-12**	**1.00E-12**	**3.13E-11**	**6.97E-09**	**6.97E-09**
Male vs Female	1.34E-01	3.24E-01	8.70E-01	1.54E-01	1.54E-01
Age					
Normal vs Age(21-40Y)	**3.02E-04**	**7.97E-05**	**5.96E-04**	1.18E-01	1.18E-01
Normal vs Age(41-60Y)	**1.00E-12**	**1.62E-12**	**1.00E-12**	**6.99E-09**	**6.99E-09**
Normal vs Age(61-80Y)	**1.00E-12**	**1.62E-12**	**8.88E-16**	**2.63E-11**	**2.62E-11**
Normal vs Age(81-100Y)	**6.01E-05**	**4.78E-04**	6.63E-02	6.04E-02	6.04E-02
Age(21-40Y) vs Age(41-60Y)	7.71E-01	9.60E-01	3.51E-01	1.07E-01	1.07E-01
Age(21-40Y) vs Age(61-80Y)	9.92E-01	8.30E-01	2.30E-01	5.29E-02	5.29E-02
Age(21-40Y) vs Age(81-100Y)	7.14E-01	6.00E-01	7.97E-01	3.96E-01	3.96E-01
Age(41-60Y) vs Age(61-80Y)	5.65E-01	6.50E-01	3.11E-01	6.42E-01	6.42E-01
Age(41-60Y) vs Age(81-100Y)	8.29E-01	5.20E-01	5.44E-01	9.01E-01	9.01E-01
Age(61-80Y) vs Age(81-100Y)	6.88E-01	4.10E-01	4.40E-01	7.43E-01	7.43E-01
Tumor grade					
Normal vs Grade 1	**5.88E-03**	**9.44E-04**	**2.44E-03**	1.33E-01	1.33E-01
Normal vs Grade 2	**1.62E-12**	**1.00E-12**	**1.62E-12**	**1.47E-07**	**1.46E-07**
Normal vs Grade 3	**1.00E-12**	**1.00E-12**	**1.62E-12**	**4.42E-09**	**4.42E-09**
Normal vs Grade 4	**2.47E-10**	**9.09E-11**	**2.80E-06**	**2.03E-05**	**2.03E-05**
Grade 1 vs Grade 2	3.15E-01	3.80E-01	9.23E-02	5.77E-01	5.77E-01
Grade 1 vs Grade 3	4.63E-01	8.50E-01	2.41E-01	9.04E-01	9.04E-01
Grade 1 vs Grade 4	6.88E-01	6.70E-01	4.44E-01	7.99E-01	7.99E-01
Grade 2 vs Grade 3	4.55E-01	1.00E-01	4.55E-01	2.47E-01	2.47E-01
Grade 2 vs Grade 4	2.92E-01	2.40E-02	3.64E-01	8.05E-02	8.05E-02
Grade 3 vs Grade 4	6.06E-01	1.77E-01	6.36E-01	4.16E-01	4.16E-01
ccRCC subtypes					
Normal vs ccA subtype	**1.11E-16**	**1.62E-12**	**4.44E-16**	**3.75E-07**	**3.75E-07**
Normal vs ccB subtype	**1.11E-16**	**1.62E-12**	**1.62E-12**	**1.95E-08**	**1.95E-08**
ccA subtype vs ccA subtype	2.91E-01	**1.46E-03**	**4.46E-02**	**2.62E-03**	**2.62E-03**
Nodal Metastasis status					
Normal vs N0	**1.00E-12**	**1.62E-12**	**5.59E-14**	**5.45E-10**	**5.45E-10**
Normal vs N1	**1.52E-03**	**1.03E-03**	**1.47E-02**	**2.56E-02**	**2.56E-02**
N0 vs N1	2.58E-01	3.21E-01	3.08E-01	7.52E-01	7.52E-01

Supplementary Figure 1. Expression of TBC1D3 Mrna in KIRC tissues. T: KIRC tissues; N: noncancerous tissues.



Supplementary Figure 2. The Human Protein Atlas database revealed that TBC1D3 was colocalized with microtubule proteins in the cytoplasm of U-2 OS and U-251 MG cells.



Supplementary Figure 3. Overall survival comparing the high and low expression of TBC1D3 family members in KIRC.



Supplementary Figure 4. Relapse-free survival comparing the high and low expression of TBC1D3 family members in KIRC. High levels of TBC1D3, TBC1D3B were associated with better prognoses while the other TBC1D3 family members were correlated with poor prognoses.